Thomas J Sayers Selected Research

Thomas J Sayers Research Topics

Disease

33	Neoplasms (Cancer) 12/2021 - 04/2002
11	Renal Cell Carcinoma (Grawitz Tumor) 12/2021 - 03/2003
9	Neoplasm Metastasis (Metastasis) 12/2015 - 01/2003
5	Kidney Neoplasms (Kidney Cancer) 08/2006 - 04/2002
4	Melanoma (Melanoma, Malignant) 12/2021 - 12/2015
3	Breast Neoplasms (Breast Cancer) 01/2014 - 04/2010
3	Graft vs Host Disease (Graft-Versus-Host Disease) 08/2008 - 05/2004
2	Prostatic Neoplasms (Prostate Cancer) 12/2021 - 01/2017
2	Neuroblastoma 04/2009 - 05/2006
1	Experimental Melanoma 01/2021
1	Adenocarcinoma 01/2017
1	Pancreatic Neoplasms (Pancreatic Cancer) 10/2015
1	Sarcoma (Soft Tissue Sarcoma) 10/2014
1	Multiple Myeloma 07/2010
1	Esophageal Squamous Cell Carcinoma 06/2010
1	Human Influenza (Influenza) 08/2009
1	Hematologic Neoplasms (Hematological Malignancy) 08/2008
1	Carcinogenesis 01/2006
1	Colonic Neoplasms (Colon Cancer) 11/2005
1	Lymphoma (Lymphomas) 06/2004
1	Leukemia 05/2004
1	Myeloid Leukemia (Leukemia, Myelocytic) 07/2003
1	Aplastic Anemia (Anemia, Hypoplastic) 05/2003

Drug/Important Bio-Agent (IBA)

12	LigandsIBA 01/2021 - 01/2003
11	Bortezomib (Velcade)FDA Link 12/2015 - 07/2003
10	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2017 - 04/2002
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2003
6	Proteasome InhibitorsIBA 12/2015 - 05/2004
5	Fas Ligand Protein (Fas Ligand)IBA 06/2014 - 04/2002
5	PerforinIBA 08/2009 - 04/2002
5	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2008 - 05/2004
4	CytokinesIBA 05/2012 - 11/2004
4	TNF-Related Apoptosis-Inducing LigandIBA 07/2010 - 05/2005
3	WithanolidesIBA 02/2017 - 01/2017
3	AntibodiesIBA 08/2011 - 01/2003
3	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 07/2010 - 02/2004
3	Interleukin-2 (IL2)IBA 04/2009 - 03/2003
2	physachenolide CIBA 12/2021 - 01/2021
2	Poly I-CIBA 12/2021 - 01/2021
2	Antineoplastic Agents (Antineoplastics)IBA 02/2017 - 01/2006
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 12/2015 - 08/2009
2	AntigensIBA 12/2015 - 08/2009
2	Death Domain ReceptorsIBA 10/2015 - 01/2003
2	Peptides (Polypeptides)IBA 05/2012 - 08/2009
2	Interleukin-12 (IL 12)IBA 05/2006 - 11/2004
1	PolynucleotidesIBA 01/2021
1	rocaglamideIBA 11/2018
1	AndrogensIBA 01/2017
1	Interleukin-2 Receptors (IL 2 Receptor)IBA 12/2015
1	Aldehyde DehydrogenaseIBA 10/2015
1	pazopanib FDA Link 10/2014
1	regorafenibIBA 10/2014
1	Sorafenib (BAY 43-9006)FDA Link 10/2014
1	Tyrosine Kinase InhibitorsIBA 10/2014
1	Secretory Leukocyte Peptidase InhibitorIBA 01/2014
1	Drug CombinationsIBA 10/2012
1	CucurbitacinsIBA 01/2012
1	Toll-Like Receptor AgonistsIBA 07/2010
1	Hazardous Substances (Hazardous Materials)IBA 06/2010
1	IsotopesIBA 06/2010
1	Caspase 8 (Caspase-8)IBA 05/2010
1	Viral HemagglutininsIBA 08/2009
1	Interleukin-27 (Interleukin 27)IBA 04/2009
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 08/2006
1	NK Cell Lectin-Like Receptor Subfamily KIBA 08/2006
1	Cycloheximide (Cicloheximide)IBA 05/2005
1	LectinsIBA 11/2004
1	InterleukinsIBA 11/2004
1	Interleukin-18 (Interleukin 18)IBA 11/2004
1	Granzymes (Granzyme)IBA 06/2004
1	Monoclonal AntibodiesIBA 02/2004
1	Fc Receptors (Fc Receptor)IBA 02/2004
1	EnzymesIBA 01/2003

Therapy/Procedure

12	Therapeutics 02/2017 - 01/2003
8	Immunotherapy 12/2021 - 11/2004
3	Bone Marrow Transplantation (Transplantation, Bone Marrow) 08/2008 - 05/2004
2	Drug Therapy (Chemotherapy) 12/2021 - 10/2012
1	Neoadjuvant Therapy 10/2014
1	Aftercare (After-Treatment) 06/2014
1	Radiotherapy 10/2012
1	Homologous Transplantation 08/2008
1	Transplantation 05/2003
1	Biological Therapy 04/2002